Peer-reviewed journal articles (5)
1.
Ando, K., Ndjim, M., Turbant, S., Fontaine, G., Pregoni, G., Dauphinot, L., Yilmaz, Z., Suain, V., Mansour, S., Authelet, M., De Dekker, R., Leroy, K., Delatour, B., Letournel, F., Martin-Négrier, M.-L., Chapon, F., Godfraind, C., Maurage, C.-A., Deramecourt, V., Meyronnet, D., Streichenberger, N., De Paula Rosa Passetti, A. P., Rigau, V., & Burel-Vandenbos, F. (2020). The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer’s disease. Acta neuropathologica communications, 8(1). doi:10.1186/s40478-020-00954-12.
Houben, S., De Fisenne, M.-A., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2020). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice. Frontiers in Molecular Neuroscience, 13, 10.3389/fnmol.2020.00106, 106.3.
Ando, K., De Decker, R., Vergara Panos, C., Yilmaz, Z., Mansour, S., Suain, V., Sleegers, K., De Fisenne, M.-A., Houben, S., Potier, M.-C., Duyckaerts, C., Watanabe, T., Buée, L., Leroy, K., & Brion, J. P. (2020). Picalm reduction exacerbates tau pathology in a murine tauopathy model. Acta Neuropathologica, 139(4), 773-789. doi:10.1007/s00401-020-02125-x4.
Poncelet, L., Ando, K., Vergara Panos, C., Mansour, S., Suain, V., Yilmaz, Z., Reygel, A., Gilissen, E., Brion, J. P., & Leroy, K. (2019). A 4R tauopathy develops without amyloid deposits in aged cat brains. Neurobiology of aging, 81, NBA10594, 200-212. doi:10.1016/j.neurobiolaging.2019.05.0245.
Vergara Panos, C., Houben, S., Suain, V., Yilmaz, Z., De Decker, R., Vanden Dries, V., Boom, A., Mansour, S., Leroy, K., Ando, K., & Brion, J. P. (2019). Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo. Acta Neuropathologica, 137(3), 397-412. doi:10.1007/s00401-018-1953-5 Papers published in national and international conferences or symposium proceedings (1)
1.
Ando, K., Pregoni, G., Verheijen, J., Vergara Panos, C., De Decker, R., Mansour, S., Yilmaz, Z., Suain, V., Dauphinot, L., Fontaine, G., Leroy, K., Duyckaerts, C., Sleegers, K., Potier, M.-C., & Brion, J. P. (2018). PICALM susceptible loci and the levels of its mRNA and protein expression. 2nd EUROtau meeting abstract book 2nd EUROtau meeting(2: 26-27 April 2018: Lille, France) Research reports, book reviews, letters to the editor, working papers (1)
1.
Ando, K., Ferlini, L., Suain, V., Yilmaz, Z., Mansour, S., Le Ber, I., Bouchard, C., Leroy, K., Durr, A., Clot, F., Sarazin, M., & Bier, J. C. (2020). De novo MAPT mutation G335A causes severe brain atrophy, 3R and 4R PHF-tau pathology and early onset frontotemporal dementia. Acta neuropathologica communications, 8(1), 94. doi:10.1186/s40478-020-00977-8 Active participation in international conferences and symposiums (20)
1.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. Paper session presented at International conference on Alzheimer and Parkinson's diseases (15-22 March 2022: Barcelona).2.
De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2022). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice.. Vol. 145 (p. 411) Abstract session presented at International conference on Alzheimer and Parkinson's diseases(15-20 Mars 2022: Barcelona).3.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models.. Vol. 130 (p. 176) Abstract session presented at International conference on Alzheimer and Parkinson’s diseases(15-22 mars 2022: Barcelona).4.
Doeraene, E., Erneux, C., Yilmaz, Z., Mansour, S., Suain, V., Turbant, S., Duyckaerts, C., Brain Bank NeuroCEB Neuropathology Network,, Schurmans, S., Brion, J. P., Leroy, K., & Ando, K. (2021). Protein level and solubility of the PI 5-phosphatase SHIP2 is altered in correlation with amyloid pathology in Alzheimer’s brains. (p. 102) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).5.
Ando, K., De Decker, R., Vergara Panos, C., Yilmaz, Z., Mansour, S., Suain, V., Slegers, K., De Fisenne, M.-A., Houben, S., Potier, M.-C., Duyckaerts, C., Watanabe, T., Buée, L., Leroy, K., & Brion, J. P. (2021). Picalm reduction exacerbates tau pathology in a murine tauopathy model. (p. 77, Poster 04) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).